Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- UCB Japan Applies for Approval of Antiepileptic Agent Lacosamide in Japan
June 29, 2015
- RaQualia Regains Domestic Rights to Dalbavancin from Allergan
June 29, 2015
- Lixiana Gets EU Regulatory Approval: Daiichi Sankyo
June 26, 2015
- EU OKs Fycompa as Adjunct Therapy for PGTC Seizures: Eisai
June 26, 2015
- Sosei Group “Not in Hurry” to License Out Compounds Obtained through Heptares Acquisition: President Tamura
June 26, 2015
- Naldemedine Meets Primary, Secondary Endpoints in Japanese PIII Study for the Treatment of OIC in Cancer Patients: Shionogi
June 26, 2015
- Novartis Seeks Japan Approval of Ceritinib
June 25, 2015
- Takeda CFO Roger to Resign in under 2 Years
June 25, 2015
- Japan Vaccine Studying Marketing Strategy for 3 Seasonal Flu Vaccines, Marketing System for Adult Vaccines as Well
June 24, 2015
- AnGes MG Grants MTPC Marketing Rights for HGF Gene Treatment for Peripheral Vascular Diseases in Japan
June 24, 2015
- Hemophilia A Treatment Candidate to Move to PIII During 2015 Based on Favorable Results in PI/II Studies: Chugai
June 24, 2015
- Lilly Japan Oncology Chief Hopeful on Cyramza Growth
June 23, 2015
- Favorable PIII Data Out for Nichi-Iko’s Remicade Biosimilar
June 23, 2015
- Biogen Idec Japan Rebranded as Biogen Japan
June 23, 2015
- Opdivo Wins European Approval for Advanced Malignant Melanoma: BMS
June 23, 2015
- Fycompa Approved as Adjunctive Treatment for Primary Generalized Tonic-Clonic Seizures in US: Eisai
June 23, 2015
- Japan Diabetes Market Grows 6.1% in FY2014: Survey
June 22, 2015
- Novartis Launches Exforge OD Tablets
June 22, 2015
- Daiichi Sankyo Initiates Multinational PIII Study of Edoxaban for Venous Thromboembolism in Cancer
June 22, 2015
- Japan to Participate in Asian PIII Trial of NC-6004 for Pancreatic Cancer: NanoCarrier
June 19, 2015
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…